Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 3/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11362111 | 0.98 | SIGMAR1 (0.47) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL27914173 | 0.98 | SIGMAR1 (0.52) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL11350469 | 0.95 | SIGMAR1 (0.50) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL22848315 | 0.90 | — | — | |
| SCHEMBL29318858 | 0.88 | SIGMAR1 (0.52) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL10080302 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL360016 | 0.82 | SIGMAR1 (0.40) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL11357504 | 0.82 | SIGMAR1 (0.40) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL6247127 | 0.82 | SIGMAR1 (0.45) | SIGMAR1CYP1A2KDM1AMAOAMAOB | |
| SCHEMBL22863886 | 0.81 | SIGMAR1 (0.41) | SIGMAR1CYP1A2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2020-02-27 | — | — | US | disclosed |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | ACADIA PHARMACEUTICALS INC. | 2018-03-29 | — | — | US | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-11-03 | — | — | US | disclosed |
| US-9458082-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9422225-B2 | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-1954669-B1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2014-10-02 | — | — | US | disclosed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | AUSPEX PHARMACEUTICALS INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005044201-A2 | PH SENSITIVE PRODRUGS OF 2,6-DIISOPROPYLPHENOL | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005011573-A2 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234050-A1 | Ph sensitive prodrugs of 2,6-diisopropylphenol | CYP2D6, CYP2B6, CYP2A6 | SIGMAR1 87/4885CYP1A2 17/4885KDM1A 598/4885 |
| US-20180256517-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
| US-20200060995-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
| US-20160318847-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
| US-20060014800-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, MC1R | SIGMAR1 4334/4885CYP1A2 2674/4885KDM1A 3057/4885 |
| US-20140296339-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
| US-20180085327-A1 | Substituted Phenethylamines With Serotoninergic And/Or Norepinephrinergic Activity | SLC6A4, HTR4, GPR34 | SIGMAR1 186/4885CYP1A2 1930/4885KDM1A 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.